101. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells.
- Author
-
Kim J, Jang H, Lee GJ, Hur Y, Keum J, Jo JK, Yun SE, Park SJ, Park YJ, Choi MJ, Kim KS, and Kim J
- Subjects
- Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung pathology, Animals, B7-H1 Antigen immunology, Cell Line, Tumor, Cell Proliferation drug effects, Gene Expression Profiling, Gene Expression Regulation, Neoplastic drug effects, Humans, Janus Kinase 2 metabolism, Lung Neoplasms genetics, Lung Neoplasms pathology, Lymphocyte Activation drug effects, Mice, Inbred C57BL, Protein Kinase Inhibitors chemistry, STAT1 Transcription Factor metabolism, Signal Transduction drug effects, T-Lymphocytes drug effects, T-Lymphocytes immunology, Treatment Outcome, Mice, Adenocarcinoma of Lung immunology, B7-H1 Antigen metabolism, Interferon-gamma pharmacology, Lung Neoplasms immunology, Protein Kinase Inhibitors pharmacology
- Abstract
In this study, we describe a novel kinase inhibitor AX-0085 which can suppress the induction of PD-L1 expression by Interferon-γ (IFN-γ) in lung adenocarcinoma (LUAD) cells. AX-0085 effectively blocks JAK2/STAT1 signaling initiated by IFN-γ treatment and prevents nuclear localization of STAT1. Importantly, we demonstrate that AX-0085 reverses the IFN-γ-mediated repression of T cell activation in vitro and enhances the anti-tumor activity of anti-PD-1 antibody in vivo when used in combination. Finally, transcriptomic analyses indicated that AX-0085 is highly specific in targeting the IFN-γ-pathway, thereby raising the possibility of applying this reagent in combination therapy with checkpoint inhibitor antibodies. It may be particularly relevant in cases in which PD-L1-mediated T cell exhaustion leads to immunoevasive phenotypes.
- Published
- 2021
- Full Text
- View/download PDF